TP53 and T-cell non-Hodgkin lymphoma: To test the potential tumorigenic risk of G6PD overexpression, we crossed G6PD-Tg mice with several genetically modified tumor-prone animals, including ATM-KO (that develop T-cell lymphomas), Eμ-myc (that develop B-cell lymphomas), p53-KO (that develop T-cell lymphomas and sarcomas), and MMTV-PyMT (that develop mammary tumors) [9,10].